An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82953-82960

  Péron, Julien ^a   Roy, Pascal ^a   Conroy, Thierry ^b   Desseigne, Françoise ^c   Ychou, Marc ^d   Gourgou Bourgade, Sophie ^d   Stanbury, Trevor ^e   Roche, Laurent ^a   Ozenne, Brice ^a   Buyse, Marc ^f  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Center Alexis Vautrin   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE VAL D AURELLE   (France)

^e R and D Department   (France)

^f International Drug Development Institute   (United States)

Author keywords

Benefit risk assessment; Multi criteria analysis; Pancreatic cancer; Randomized controlled trial; Statistics as topic

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; METASTASIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SURVIVAL TIME; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; PANCREAS TUMOR; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85003815070     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12761     Document Type: Article

References (18)

1. US Food and Drug Administration. Guidance for Industry and Food and Drug Administration Staff-Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approvals and De Novo Classifications. 2012. Available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Guidance Documents/ucm267829.htm.
2. Committee for Medicinal Products for Human Use (CHMP) E. Report of the CHMP working group on benefit-risk assessment models and methods. http//www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_ guideline/2010/01/WC500069668.pdf (last accessed 25 june 2015). 2008.
3. Péron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013; 31:3957-63 doi:10.1200/JCO.2013.49.3981.
4. Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012; 104:982-9. doi:10.1093/jnci/djs259.
5. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-13.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-nomikos T, Ptasynski M, Parulekar W. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960-1966. doi:10.1200/JCO.2006.07.9525.
7. Péron J, Roy P, Ding K, Parulekar W, Roche L, Buyse M. Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. Br J Cancer. 2015; 112:971-6. doi:10.1038/bjc.2015.55.
8. Conroy T, Desseigne F, Ychou M. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364:1817-1825.
9. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW. FOLFIRINOX in locally advanced pancreatic cancer: the Massachussetts General Hospital Cancer Center experience. Oncologist. 2013; 18:543-548.
10. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691-703. doi:10.1056/NEJMoa1304369.
11. Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Stat Med. 2010; 29:3245-3257. doi:10.1002/sim.3923.
12. Péron J, Roy P, Ozenne B, Roche L, Buyse M. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. JAMA Oncol. 2016 Jul 1; 2:901-5. doi:10.1001/jamaoncol.2015.6359.
13. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009; 12:S5-9. doi:10.1111/j.1524-4733.2009.00515.x.
14. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010; 96:5-21. doi:10.1093/bmb/ldq033.
15. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011; 377:1749-59. doi:10.1016/S0140-673660399-1.
16. Péron J, Buyse M, Ozenne B, Roche L, Roy P. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Stat Methods Med Res. 2016 Aug 2. pii: 0962280216658320. [Epub ahead of print].
17. Moser BK, McCann MH. Reformulating the hazard ratio to enhance communication with clinical investigators. Clin Trials. 2008; 5:248-252. doi:5/3/248 [pii] 10.1177/1740774508091452.
18. Buyse M. Reformulating the hazard ratio to enhance communication with clinical investigators. Clin Trials. 2008; 5:641-642. doi:5/6/641 [pii] 10.1177/1740774508098328.